Senseonics Holdings Enters Agreement with Abbott Laboratories

Senseonics Holdings ( (SENS) ) has issued an announcement.

On May 15, 2025, Senseonics Holdings entered into a securities purchase agreement with Abbott Laboratories to sell up to $25 million of its common stock in a private placement, contingent upon the closing of a proposed public offering. This strategic move includes granting Abbott certain negotiation rights for potential future transactions, which could impact the company’s operational and market strategies. The agreement reflects Senseonics’ efforts to strengthen its financial position and explore strategic opportunities, potentially affecting stakeholders and the company’s industry positioning.

The most recent analyst rating on (SENS) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Senseonics Holdings stock, see the SENS Stock Forecast page.

Spark’s Take on SENS Stock

According to Spark, TipRanks’ AI Analyst, SENS is a Neutral.

Senseonics Holdings shows promise with revenue growth and strategic partnerships, but is hindered by negative profitability, high debt, and valuation challenges. The earnings call provided a positive outlook, yet operational and financial risks remain significant.

To see Spark’s full report on SENS stock, click here.

More about Senseonics Holdings

Senseonics Holdings, Inc. operates in the medical technology industry, focusing on the development and commercialization of long-term implantable continuous glucose monitoring (CGM) systems. Their primary products include the Eversense® CGM systems, which are designed for people with diabetes to monitor glucose levels over extended periods. The company targets the large and growing Type 1 and Type 2 diabetes patient populations with its innovative CGM solutions.

Average Trading Volume: 5,489,156

Technical Sentiment Signal: Sell

Current Market Cap: $389.8M

See more data about SENS stock on TipRanks’ Stock Analysis page.